JPH10245391A5 - - Google Patents
Info
- Publication number
- JPH10245391A5 JPH10245391A5 JP1997047963A JP4796397A JPH10245391A5 JP H10245391 A5 JPH10245391 A5 JP H10245391A5 JP 1997047963 A JP1997047963 A JP 1997047963A JP 4796397 A JP4796397 A JP 4796397A JP H10245391 A5 JPH10245391 A5 JP H10245391A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- acceptable salt
- active ingredient
- physiologically acceptable
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9047963A JPH10245391A (ja) | 1997-03-03 | 1997-03-03 | ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9047963A JPH10245391A (ja) | 1997-03-03 | 1997-03-03 | ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10245391A JPH10245391A (ja) | 1998-09-14 |
| JPH10245391A5 true JPH10245391A5 (fr) | 2004-12-02 |
Family
ID=12790005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9047963A Pending JPH10245391A (ja) | 1997-03-03 | 1997-03-03 | ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10245391A (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| US6670391B2 (en) | 2001-06-28 | 2003-12-30 | Dainippon Ink And Chemicals, Inc. | Benzopyran derivative and antiallergic agent |
| TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
| US8791077B2 (en) | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| US9545610B2 (en) | 2013-03-04 | 2017-01-17 | Nova Chemicals (International) S.A. | Complex comprising oxidative dehydrogenation unit |
| CN104945455B (zh) * | 2014-03-28 | 2019-01-01 | 中国医学科学院药物研究所 | 香豆素苷类化合物、其制法和药物组合物与用途 |
| CN104861020B (zh) * | 2015-06-14 | 2017-05-17 | 海南医学院 | 一个苯丙素苷类化合物、其提取方法及其应用 |
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
| AU2021202643B2 (en) | 2020-07-27 | 2023-02-02 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| EP4315350A1 (fr) | 2021-04-01 | 2024-02-07 | AstraZeneca UK Limited | Systèmes et méthodes de gestion de prédiabète à l'aide d'une composition pharmaceutique d'inhibiteur de cotransport 2 de sodium-glucose à base de gliflozine |
| WO2025125513A1 (fr) | 2023-12-15 | 2025-06-19 | AstraZeneca Ireland Limited | Inhibiteurs de sglt2 et baxdrostat pour le traitement d'une maladie rénale chronique et de l'hypertension |
-
1997
- 1997-03-03 JP JP9047963A patent/JPH10245391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10245391A5 (fr) | ||
| CA2136999A1 (fr) | Agent de vasodilation peripherique contenant un derive de la piperidine comme ingredient actif | |
| CA2382480A1 (fr) | Derives de glucopyranosyloxypyrazole, compositions medicinales renfermant lesdits derives et produits intermediaires obtenus au cours de leur production | |
| CA2309350A1 (fr) | Derives de purine et medicament les renfermant en tant qu'ingredient actif | |
| PL315636A1 (en) | Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives | |
| CA2015475A1 (fr) | Agent pour le traitement de l'osteoarthrite | |
| IL112515A (en) | Pharmaceutical composition containing N,N-dimethyl-1-¬1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine for use in the treatment of non-insulin dependent diabetes mellitus | |
| CA2102591A1 (fr) | Agent hypoglycemiant | |
| CA2257016A1 (fr) | Derives d'imidazolidin-4-one utiles comme agents anticancereux | |
| JP2002519425A5 (fr) | ||
| KR950016723A (ko) | 자가면역 질병의 억제 방법 | |
| KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
| CA2190993A1 (fr) | Agent protecteur pour organe ou tissu | |
| RU2003134629A (ru) | Соединения цефема | |
| CA2365359A1 (fr) | Medicaments contenant des derives du sulfopyranosylacylglyce | |
| TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
| JP2000169325A5 (fr) | ||
| KR960706472A (ko) | 프로스타글란딘 유도체, 그의 염 및 그의 사용 | |
| CA2317673A1 (fr) | Nouveaux derives d'allylthiopyridazine et leur procede de preparation | |
| CA2373484A1 (fr) | Utilisation de derives 1,4-benzothiazepine en tant que medicaments contre la tolerance cancerostatique | |
| EP1103253A3 (fr) | Agent filmogène aqueux de revêtement et préparation solide à utilisation orale | |
| IT1254280B (it) | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson | |
| KR950032264A (ko) | 7-글리코실옥시벤조피란 유도체 및 이를 활성 성분으로서 함유하는 항알레르기제 | |
| RU97112927A (ru) | Новое аминоолигосахаридное производное и способ его получения | |
| JPH09249688A5 (fr) |